<table id="ID183" width="100%" xmlns="urn:hl7-org:v3" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<caption>Table 5. Established and Other Potentially Significant Drug Interactions</caption>
<col width="27%"></col>
<col width="29%"></col>
<col width="44%"></col>
<tfoot>
<tr>
<td align="left" colspan="3">
<paragraph stylecode="Footnote">↓ = Decreased (induces lamotrigine glucuronidation).<br/>
</paragraph>
</td>
</tr>
<tr>
<td align="left" colspan="3">
<paragraph stylecode="Footnote">↑ = Increased (inhibits lamotrigine glucuronidation).<br/>
</paragraph>
</td>
</tr>
<tr>
<td align="left" colspan="3">
<paragraph stylecode="Footnote">? = Conflicting data.<br/>
</paragraph>
</td>
</tr>
</tfoot>
<tbody>
<tr>
<td align="left" stylecode=" Lrule Rrule Botrule Toprule" valign="top">Concomitant Drug<br/>
</td>
<td align="left" stylecode=" Lrule Rrule Botrule Toprule" valign="top">Effect on Concentration of Lamotrigine or Concomitant Drug<br/>
</td>
<td align="left" stylecode=" Lrule Rrule Botrule Toprule" valign="top">Clinical Comment<br/>
</td>
</tr>
<tr>
<td align="left" stylecode=" Lrule Rrule Botrule Toprule" valign="top">Estrogen-containing oral contraceptive preparations containing 30 mcg ethinylestradiol and 150 mcg levonorgestrel<br/>
</td>
<td align="left" stylecode=" Lrule Rrule Botrule Toprule" valign="top">↓ lamotrigine<br/>
<br/>↓ levonorgestrel<br/>
<br/>
</td>
<td align="left" stylecode=" Lrule Rrule Botrule Toprule" valign="top">Decreased lamotrigine levels approximately 50%.<br/>Decrease in levonorgestrel component by 19%.<br/>
<br/>
</td>
</tr>
<tr>
<td align="left" stylecode=" Lrule Rrule Botrule Toprule" valign="top">Carbamazepine and<br/>carbamazepine epoxide<br/>
<br/>
</td>
<td align="left" stylecode=" Lrule Rrule Botrule Toprule" valign="top">↓ lamotrigine<br/>
<br/>
<br/>? CBZ epoxide<br/>
<br/>
</td>
<td align="left" stylecode=" Lrule Rrule Botrule Toprule" valign="top">Addition of carbamazepine decreases <br/>lamotrigine concentration approximately 40%.<br/>May increase carbamazepine epoxide levels.<br/>
</td>
</tr>
<tr>
<td align="left" stylecode=" Lrule Rrule Botrule Toprule" valign="top">Phenobarbital/Primidone<br/>
</td>
<td align="left" stylecode=" Lrule Rrule Botrule Toprule" valign="top">↓ lamotrigine<br/>
<br/>
</td>
<td align="left" stylecode=" Lrule Rrule Botrule Toprule" valign="top">Decreased lamotrigine concentration approximately 40%.<br/>
</td>
</tr>
<tr>
<td align="left" stylecode=" Lrule Rrule Botrule Toprule" valign="top">Phenytoin<br/>
</td>
<td align="left" stylecode=" Lrule Rrule Botrule Toprule" valign="top">↓ lamotrigine<br/>
<br/>
</td>
<td align="left" stylecode=" Lrule Rrule Botrule Toprule" valign="top">Decreased lamotrigine concentration approximately 40%.<br/>
</td>
</tr>
<tr>
<td align="left" stylecode=" Lrule Rrule Botrule Toprule" valign="top">Rifampin<br/>
</td>
<td align="left" stylecode=" Lrule Rrule Botrule Toprule" valign="top">↓ lamotrigine<br/>
<br/>
</td>
<td align="left" stylecode=" Lrule Rrule Botrule Toprule" valign="top">Decreased lamotrigine AUC approximately 40%.<br/>
</td>
</tr>
<tr>
<td align="left" stylecode=" Lrule Rrule Botrule Toprule" valign="top">Valproate<br/>
</td>
<td align="left" stylecode=" Lrule Rrule Botrule Toprule" valign="top">↑ lamotrigine<br/>
<br/>? valproate<br/>
</td>
<td align="left" stylecode=" Lrule Rrule Botrule Toprule" valign="top">Increased lamotrigine concentrations slightly more than 2-fold.<br/>
<br/>Decreased valproate concentrations an average of 25% over a 3-week period then stabilized in healthy volunteers; no change in controlled clinical trials in epilepsy patients.<br/>
</td>
</tr>
</tbody>
</table>